Lawyers Injectafer Cases
Our Defective Drug Lawyers are Reviewing Injectafer Lawsuits
Research indicates that Injectafer might cause a dangerous and often fatal condition called hypophosphatemia (HPP). Injectafer is an injectable medical iron supplement used to treat adults with iron deficiency anemia and chronic kidney disease. The drug is supposed to increase the amount of iron in the patient’s blood.
Clinical research shows that Injectafer significantly increases the risk of a patient developing HPP. Despite the evidence, drug companies selling Injectafer do not warn doctors and patients of this serious and potentially deadly side effect.
At Alonso Krangle, LLP, our defective drug lawyers are investigating lawsuits involving Injectafer and HPP. If you or someone you love was injured because of Injectafer, call our lawyers for a free evaluation of your case. If you suffered harm because of a defective iron anemia deficiency drug, you might have the right to obtain damages. Call Alonso Krangle, LLP, at 800-403-6191 to find out if you qualify to file an Injectafer lawsuit.
What is Injectafer? And Why do Doctors Prescribe it?
Injectafer is a form of FCM- or ferric carboxymaltose. It is a medication used to replace iron in the body when the iron is deficient. Administered as an IV over two sessions that occur at least one week apart, Injectafer works by slowly releasing iron into the patient’s blood.
There are a variety of entities involved in the production and selling of Injectafer. They include:
- Luitpold Pharmaceuticals, Inc.
- American Regent, Inc.
- Daiichi Sankyo, Inc.
- Daiichi Sankyo Co., LTD
- Daiichi Sankyo US Holdings, Inc.
- Vifor Pharmaceuticals Management, LTD
Doctors prescribe Injectafer to adults who have iron deficiency anemia and, for a variety of reasons, cannot or don’t respond well to oral iron supplements. Doctors also use Injectafer for patients with chronic kidney disease who are not getting dialysis treatment.
Injectafer is being used frequently. It is the fastest-growing form of IV iron infusions in the country. There are indications, however, that Injectafer may not be as safe as the public and medical professionals initially thought.
Clinical safety studies show that Injectafer increases the risk of HPP and severe HPP and does so at a rate much higher than alternative treatments.
What Is Hypophosphatemia (HPP)?
Phosphates are a combination of phosphorus and oxygen. HPP exists when the levels of phosphates in your blood become abnormally and dangerously low. When phosphates become low, it causes symptoms, which can become dangerous and compromise your health and safety.
We get phosphates when we eat foods containing phosphorus, and the food combines with oxygen during digestion. Phosphates play an important role in repairing and maintaining the health of teeth, bones, muscles, and nerves. Foods like eggs, meat, and beans are good sources of phosphorous.
When you have HPP, and your phosphate is too low, your body cannot maintain normal functions.
HPP can be mild and have minimal side effects before treating it without complications. However, when HPP symptoms become worse, and phosphate levels continue to decline, the results can be fatal.
How Dangerous Is Hypophosphatemia Caused by Injectafer?
HPP can range from mild to severe. If HPP is left untreated, it can result in a range of symptoms including:
- Muscle pain
- Heart failure
- Wasting of muscles
- Bone pain and fractures
- Respiratory distress
- Acute hemolytic anemia
If you or someone you love experienced any of these symptoms during your treatment for iron deficiency anemia or kidney disease, call our lawyers for more information about filing an Injectafer lawsuit.
Clinical Studies Link Injectafer to Increased Risks of HPP and Severe HPP
The primary study linking Injectafer to an increase in HPP was conducted by Austrian researchers in 2016. The study compared the rate of HPP and severe HPP in patients injected with FCM, the type of iron in Injectafer, with those injected with isomaltoside, the type of iron found in another kind of iron supplement. The results?
Nearly half of those who received FCM injections developed HPP. 32.7% developed severe HPP. Of those who received isomaltoside, 4% developed HPP, and there were no cases of severe HPP.
Studies conducted in 2013, 2015, and 2017 reached similar conclusions about using FCM – that it caused a substantially higher number of incidents of HPP and severe HPP than other types of iron deficiency anemia treatments.
Drug Companies Must Warn People About Dangers
Lawsuits being filed alleging that the makers of Injectafer knew or should have known about these dangers and do not provide adequate warnings the laws require. Injectafer warns that patients may experience headaches and nausea and low levels of phosphorus in the blood. Nowhere is there mention of the dangerous and possibly fatal risk of HPP.
Call Our Defective Drug Lawyers Who Are Reviewing Injectafer Lawsuits
Ask yourself: “Do I have an Injectafer lawsuit?” Find out by calling our defective drug lawyers at Alonso Krangle, LLP.
If you or someone you love was treated for iron deficiency anemia with Injectafer:
- Were there side effects from Injectafer?
- Did you learn about treatment options other than Injectafer?
- Did you receive a warning about the side effects?
- Did you develop HPP or Severe HPP?
- Did you have other serious side effects?
If so, contact our lawyers right away to find out if you are eligible to file a lawsuit against the makers of Injectafer. You might be able to obtain damages for your injuries caused by this defective drug.
Call Alonso Krangle, LLP, lawyers reviewing Injectafer Lawyers today at 800 403-6191.